Patents by Inventor Alessandro Moretta

Alessandro Moretta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070231322
    Abstract: The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative disorders such as NK-type LDGL, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to receptors present on the surface of the proliferating cells underlying the disorders.
    Type: Application
    Filed: April 29, 2005
    Publication date: October 4, 2007
    Applicants: Innate Pharma, S.A., Universita Di Genova
    Inventors: Francois Romagne, Alessandro Moretta
  • Publication number: 20070065875
    Abstract: The present invention relates to a novel protein, termed NTB-A, nucleic acid molecules encoding the same and uses thereof. The invention also relates to methods of regulating Natural Killer cells activity by regulating the activity of NTB-A in vitro, ex vivo or in vivo. The invention also comprises methods of screening active compounds using NTB-A or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide.
    Type: Application
    Filed: November 16, 2006
    Publication date: March 22, 2007
    Applicants: Innate Pharma, S.A., Universita Di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Publication number: 20060280740
    Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
    Type: Application
    Filed: January 3, 2006
    Publication date: December 14, 2006
    Applicant: Novo Nordisk A/S
    Inventors: Soren Padkjaer, Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Peter Reumert Wagtmann
  • Publication number: 20060263361
    Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
    Type: Application
    Filed: July 1, 2004
    Publication date: November 23, 2006
    Applicants: Innate Pharma S.A., Universita Di Genova
    Inventors: Alessandro Moretta, Mariella Della Chiesa
  • Patent number: 7138243
    Abstract: The present invention relates to a novel protein, termed NTB-A, nucleic acid molecules encoding the same and uses thereof. The invention also relates to methods of regulating Natural Killer cells activity by regulating the activity of NTBA-A in vitro, ex vivo or in vivo. The invention also comprises methods of screening active compounds using NTB-A or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: November 21, 2006
    Assignees: Innate Pharma, S.A., University of Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Publication number: 20060246068
    Abstract: The invention relates to polypeptides having a triggering NK activity and an aminoacid sequence that is at least 80% identical over its entire length to the polypeptide having SEQ ID NO: 1, and any immunogenic fragments thereof, as well as to the polyclonal and monoclonal antibodies directed against said polypeptides, and immuno-reactive fragments thereof. Application for detecting NK cells in a sample, for their removal from a sample or for enrichment of NK cells, and for NK cell natural cytotoxicity regulation.
    Type: Application
    Filed: July 10, 2006
    Publication date: November 2, 2006
    Applicants: Innate Pharma, Universita di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Patent number: 7074409
    Abstract: The invention relates to polypeptides having a triggering NK activity and an aminoacid sequence that is at least 80% identical over its entire length to the polypeptide having SEQID N°1, and any immunogenic fragments thereof, as well as to the polyclonal and monoclonal antibodies directed against said polypeptides, and immuno-reactive fragments thereof. Application for detecting NK cells in a sample, for their removal from a sample or for enrichment of NK cells, and for NK cell natural cytotoxicity regulation.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: July 11, 2006
    Assignees: Innate Pharma, Universita di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Patent number: 6979546
    Abstract: The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.
    Type: Grant
    Filed: January 7, 2002
    Date of Patent: December 27, 2005
    Assignees: Universita di Genova, Innate Pharma S.A.S.
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Publication number: 20050221438
    Abstract: The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.
    Type: Application
    Filed: May 25, 2005
    Publication date: October 6, 2005
    Applicants: Innate Pharma, Universita Di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Publication number: 20050159332
    Abstract: The present invention relates to a novel protein, termed NTB-A, nucleic acid molecules encoding the same and uses thereof. The invention also relates to methods of regulating Natural Killer cells activity by regulating the activity of NTBA-A in vitro, ex vivo or in vivo. The invention also comprises methods of screening active compounds using NTB-A or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide.
    Type: Application
    Filed: July 17, 2002
    Publication date: July 21, 2005
    Applicants: Innate Pharma, Universita Di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Publication number: 20050130130
    Abstract: The invention concerns novel means for diagnosing, preventing, compensating, treating an abnormal or unwanted functioning of KAR receptors (Killer cell Activatory Receptor, counterparts of non-inhibiting KIR receptors (Keller cell Inhibitory Receptors) of the immunoglobulin or lectin type. The invention concerns in particular, novel KARAP (KAR-Associated Proteins) polypeptides and their biological applications. A KARAP polypeptide is naturally associated with a KAR receptor, and in the absence of such a KARAP, said KAR receptor is naturally incapable of transducing an activating signal that can be detected. The application also concerns methods for obtaining or identifying such KARAP polypeptides.
    Type: Application
    Filed: August 2, 2004
    Publication date: June 16, 2005
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Eric Vivier, Alessandro Moretta, Lucia Olcese, Frederic Vely, Elena Tomasello
  • Publication number: 20040115738
    Abstract: The invention relates to polypeptides having a triggering NK activity and an aminoacid sequence that is at least 80% identical over its entire length to the polypeptide having SEQ ID NO 1, and any immunogenic fragments thereof, as well as to the polyclonal and monoclonal antibodies directed against said polypeptides, and immuno-reactive fragments thereof. Application for detecting NK cells in a sample, for their removal from a sample or for enrichment of NK cells, and for NK cell natural cytotoxicity regulation.
    Type: Application
    Filed: August 27, 2003
    Publication date: June 17, 2004
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Publication number: 20030077285
    Abstract: p75/AIRM1 is expressed on myeloid cells at stages of differentiation and determination of its presence is useful in monitoring cellular proliferation and determining proliferative states of cells, especially myeloid cells in diseases such as chronic myeloid leukemia. Ligands such as antibody molecules, for instance the QA79 monoclonal antibody deposited under accession number ICLC No. PD99003, are useful for methods of diagnosis and treatment, e.g. by way of inhibition of cellular proliferation and induction of apoptosis in cells.
    Type: Application
    Filed: October 2, 2002
    Publication date: April 24, 2003
    Inventors: Roberto Biassoni, Alessandro Moretta, Lorenzo Moretta, Maria Cristina Mingari
  • Publication number: 20020142445
    Abstract: The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytotoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.
    Type: Application
    Filed: January 7, 2002
    Publication date: October 3, 2002
    Applicant: Universita di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni